Henagliflozin on Myocardial Fibrosis in Obese Patients (LY2026-317-C)
Effect of Henagliflozin on Myocardial Fibrosis in Obese Patients: A Prospective, Randomized, Controlled Study.
This study evaluates the anti-fibrotic efficacy and safety of henagliflozin versus metformin in non-diabetic obese patients with subclinical myocardial fibrosis, explores whether the benefit is mediated by metabolic improvement or direct myocardial protection, and aims to provide high-level evidence for early pharmacological intervention.
調査の概要
詳細な説明
This study will be based on an established specialized cohort of non-diabetic patients with simple obesity and a multi-omics database. By integrating clinical data with multidimensional information including genomics, metabolomics, and proteomics, patients at high risk of myocardial fibrosis will be identified. After myocardial fibrotic changes are further confirmed by CMR, eligible participants will be randomly assigned to the control group (metformin) or the intervention group (henagliflozin). The treatment period will be 24 weeks, followed by a 24-week safety follow-up period. The difference in the change in the degree of myocardial fibrosis before and after treatment between the two groups will be compared to determine the efficacy of henagliflozin in counteracting myocardial fibrosis in the non-diabetic obese population. This project aims to provide high-level evidence-based medical evidence for targeted pharmacological intervention of obesity-related early cardiac damage, with the goal of improving the long-term prognosis of this population.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Jing Ma
- 電話番号:021-68383420
- メール:majing3436@163.com
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- BMI ≥ 28 kg/m², or waist circumference ≥ 90 cm in men or ≥ 85 cm in women, or body fat percentage ≥ 25% in men or ≥ 30% in women;
- Adults aged 18 to 65 years;
- ECV greater than 30%;
- No participation in other clinical trials within the past three months.
Exclusion Criteria:
- Diagnosed with diabetes mellitus or prediabetes;
- History of coronary artery disease (coronary stenosis > 50% on coronary angiography or coronary computed tomography), history of myocardial infarction, history of coronary artery bypass grafting or percutaneous coronary intervention; non-ischemic cardiovascular diseases such as idiopathic cardiomyopathy, valvular disease, congenital heart disease, or cor pulmonale; arrhythmia or bundle branch block on electrocardiogram; implantation of a cardiac pacemaker or defibrillator;
- Uncontrolled hypertension: systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg during the screening visit (mean of three blood pressure measurements in the supine position);
- Symptomatic hypotension and/or systolic blood pressure < 90 mmHg at V1 or V2, or patients judged by the clinician to have hypovolemia;
- Use within 3 months of: 1) medications that may affect body weight or glucose metabolism, including systemic glucocorticoids (excluding topical, ophthalmic, nasal spray, or inhaled preparations; excluding low-dose or overnight dexamethasone suppression test use), growth hormone, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic/tetracyclic antipsychotic drugs, other psychiatric medications or sedatives (e.g., imipramine, amitriptyline, mirtazapine, paroxetine, phenelzine, chlorpromazine, thioridazine, clozapine, olanzapine, valproic acid, valproic acid derivatives, lithium salts), etc.; 2) traditional Chinese medicines, Chinese patent medicines, herbal medicines, health supplements, meal replacements, etc., with weight-loss or glucose-lowering effects; 3) use of or current use of the following weight-loss drugs or drugs containing the following ingredients, such as: sibutramine hydrochloride, orlistat, phentermine, phenylpropanolamine, clobenzorex, fenfluramine, amfepramone, lorcaserin, phentermine/topiramate combination, naltrexone/bupropion combination, etc.; 4) use of glucose-lowering drugs, such as metformin, α-glucosidase inhibitors, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, thiazolidinediones (TZDs), insulin, etc.;
- Other endocrine and metabolic diseases such as hyperthyroidism, hypothyroidism, acromegaly, diabetes insipidus, or Cushing's syndrome;
- Concurrent malignant tumors;
- Severe liver disease (Child-Pugh class C) or liver enzymes (ALT/AST) > 3 times the upper limit of normal;
- Estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73 m²;
- Cognitive impairment, or concomitant infectious or autoimmune diseases;
- History of recurrent urinary or reproductive tract infections;
- Patients who refuse henagliflozin or metformin treatment, or who are allergic to henagliflozin, metformin, or their excipients; those with incomplete questionnaires or incomplete data;
- Pregnant or breastfeeding women.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:介入グループ
|
Oral henagliflozin 10 mg once daily for 24 weeks, administered at a fixed dose without adjustment. Used in non-diabetic obese patients with subclinical myocardial fibrosis as an off-label investigational treatment. |
|
アクティブコンパレータ:Control Group
oral metformin tablets 2000 mg/day; or the maximum tolerated dose (≥1000 mg/day). |
Oral metformin titrated to 2000 mg/day (1000 mg twice daily), or the maximum tolerated dose (≥1000 mg/day), for 24 weeks. Dose titration: 500 mg twice daily for weeks 1-2, then 1000 mg twice daily from week 3 if tolerated. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change from Baseline in Myocardial Extracellular Volume (ECV) Fraction at 24 Weeks
時間枠:Baseline to Week 24
|
Change from baseline in myocardial extracellular volume (ECV) fraction, as measured by cardiac magnetic resonance (CMR) T1 mapping pre- and post-contrast. ECV is calculated from pre- and post-contrast T1 relaxation times and the patient's hematocrit. The between-group difference in ΔECV (Henagliflozin vs. Metformin) will be compared; continuous data will be summarized as mean ± SD and analyzed using mixed-effects models. |
Baseline to Week 24
|
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
Change from Baseline in Epicardial Adipose Tissue (EAT) Volume at 24 Weeks
時間枠:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Left Ventricular Ejection Fraction (LVEF) at 24 Weeks
時間枠:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Cardiac Output at 24 Weeks
時間枠:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Heart Rate at 24 Weeks
時間枠:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Peak Filling Rate at 24 Weeks
時間枠:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Stroke Volume Index (BSA-corrected) at 24 Weeks
時間枠:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in End-Systolic Volume Index (BSA-corrected) at 24 Weeks
時間枠:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in End-Diastolic Volume Index (BSA-corrected) at 24 Weeks
時間枠:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Left Ventricular Mass Index (BSA-corrected) at 24 Weeks
時間枠:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Early-to-Late Filling Ratio (E/A) at 24 Weeks
時間枠:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in LV Mass to End-Diastolic Volume Ratio (MVR) at 24 Weeks
時間枠:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Cardiac Index at 24 Weeks
時間枠:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Body Weight at 24 Weeks
時間枠:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Body Mass Index (BMI) at 24 Weeks
時間枠:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Systolic Blood Pressure at 24 Weeks
時間枠:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Diastolic Blood Pressure at 24 Weeks
時間枠:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Glycated Hemoglobin (HbA1c) at 24 Weeks
時間枠:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Fasting Plasma Glucose at 24 Weeks
時間枠:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in HOMA-IR (Insulin Resistance Index) at 24 Weeks
時間枠:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Total Cholesterol at 24 Weeks
時間枠:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at 24 Weeks
時間枠:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at 24 Weeks
時間枠:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Triglycerides at 24 Weeks
時間枠:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in High-sensitivity CRP (hsCRP) at 24 Weeks
時間枠:Baseline to Week 24
|
Baseline to Week 24
|
その他の成果指標
結果測定 |
時間枠 |
|---|---|
|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
時間枠:Up to 48 Weeks
|
Up to 48 Weeks
|
|
Number of Participants With Genitourinary Tract Infections
時間枠:Up to 48 Weeks
|
Up to 48 Weeks
|
|
Number of Participants With Gastrointestinal Adverse Events
時間枠:Up to 48 Weeks
|
Up to 48 Weeks
|
|
Number of Participants With Ketoacidosis
時間枠:Up to 48 Weeks
|
Up to 48 Weeks
|
|
Number of Participants With Serious Adverse Events (SAEs)
時間枠:Up to 48 Weeks
|
Up to 48 Weeks
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Jing Ma、Department of Endocrinology, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- LY2026-317-C
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。